DE60131975D1 - Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten - Google Patents

Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten

Info

Publication number
DE60131975D1
DE60131975D1 DE60131975T DE60131975T DE60131975D1 DE 60131975 D1 DE60131975 D1 DE 60131975D1 DE 60131975 T DE60131975 T DE 60131975T DE 60131975 T DE60131975 T DE 60131975T DE 60131975 D1 DE60131975 D1 DE 60131975D1
Authority
DE
Germany
Prior art keywords
protein
nucleic acid
operably linked
acid encoding
regulatory elements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60131975T
Other languages
English (en)
Other versions
DE60131975T2 (de
Inventor
David B Weiner
Jeong Im Sin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of DE60131975D1 publication Critical patent/DE60131975D1/de
Application granted granted Critical
Publication of DE60131975T2 publication Critical patent/DE60131975T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE60131975T 2000-07-27 2001-07-27 Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten Expired - Fee Related DE60131975T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22102500P 2000-07-27 2000-07-27
US221025P 2000-07-27
PCT/US2001/023648 WO2002010410A1 (en) 2000-07-27 2001-07-27 Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses

Publications (2)

Publication Number Publication Date
DE60131975D1 true DE60131975D1 (de) 2008-01-31
DE60131975T2 DE60131975T2 (de) 2008-12-18

Family

ID=22826021

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131975T Expired - Fee Related DE60131975T2 (de) 2000-07-27 2001-07-27 Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten

Country Status (8)

Country Link
US (1) US7569218B2 (de)
EP (1) EP1305435B1 (de)
JP (1) JP2004505113A (de)
AT (1) ATE381351T1 (de)
AU (2) AU2001284672B2 (de)
CA (1) CA2417364A1 (de)
DE (1) DE60131975T2 (de)
WO (1) WO2002010410A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7717271B2 (en) * 2005-12-07 2010-05-18 General Electric Company Membrane structure and method of making
US20070131609A1 (en) * 2005-12-08 2007-06-14 General Electric Company Membrane structure and method of making
US8207854B2 (en) * 2009-02-09 2012-06-26 Mach 1 Development, Inc. Shipping container integrity device and system
CN102458463B (zh) * 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
US20130195961A1 (en) * 2010-03-09 2013-08-01 Kejian Yang Novel mucosal vaccination approach for herpes simplex virus type-2
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2782597B1 (de) 2011-11-23 2022-04-13 Genocea Biosciences, Inc. Nukleinsäureimpfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion
EP3519427A4 (de) 2016-09-28 2020-03-11 Genocea Biosciences Inc. Verfahren und zusammensetzungen zur behandlung von herpes
US20240091380A1 (en) 2021-02-01 2024-03-21 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0465529B1 (de) 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5676954A (en) * 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
DE69333814T2 (de) 1992-03-11 2006-02-02 Powderject Vaccines, Inc., Madison Genetischer impfstoff gegen den immunschwäche virus
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994027612A1 (en) * 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995033835A1 (en) * 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
KR100564268B1 (ko) * 1996-10-23 2006-03-27 와이어쓰 백신
EP1078093B1 (de) * 1998-02-27 2011-06-08 The Trustees of The University of Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben

Also Published As

Publication number Publication date
AU2001284672B2 (en) 2007-05-24
EP1305435B1 (de) 2007-12-19
US20040014705A1 (en) 2004-01-22
ATE381351T1 (de) 2008-01-15
EP1305435A1 (de) 2003-05-02
EP1305435A4 (de) 2004-06-16
WO2002010410A1 (en) 2002-02-07
DE60131975T2 (de) 2008-12-18
US7569218B2 (en) 2009-08-04
JP2004505113A (ja) 2004-02-19
AU8467201A (en) 2002-02-13
CA2417364A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
WO2002012341A3 (en) Her-2/neu fusion proteins
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
GEP19981289B (en) Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
ATE512231T1 (de) Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
WO2023094713A3 (en) Coronavirus vaccine
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
PT1238086E (pt) Vacina para aumentar as respostas imunes a vacina contra virus herpes simples
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
ATE378351T1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DE69529235D1 (de) Menschliche dnase i varianten
WO1998049303A3 (en) Compositions and methods for conferring tick immunity and preventing tick borne diseases
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
SE9901548D0 (sv) Helicobacter pylori antigens
UA41237A (uk) Спосіб виготовлення вакцинальних алергенів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee